Off-label information dissemination for serious illnesses will be studied by AMA board.
Executive Summary
OFF-LABEL USE INFORMATION DISSEMINATION FOR CATASTROPHIC ILLNESS will be studied by the American Medical Association under a resolution adopted by the AMA House of Delegates June 25 at its annual meeting in Chicago. The policy directs the AMA Board of Trustees to prepare "an in-depth study of the scientific, legal and regulatory aspects of this complicated issue," according to materials presented by the Reference Committee on Science & Technology, which recommended the action to the full House.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth